Hao-Yu Wang, MD, PhD, FSCAI, is an interventional cardiologist at Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College. He received his MD from China Medical University and his PhD from Peking Union Medical College. He completed his residency in internal medicine, fellowship in cardiovascular medicine, and fellowship in interventional cardiology at the Fuwai Hospital. He is a Fellow of the Society for Cardiovascular Angiography and Interventions (FSCAI) and the American College of Cardiology (FACC). His research interests include interventional cardiology, coronary physiology, and antithrombotic therapies. He has performed a series of studies on left main disease and coronary physiology, which provided important insights in this field. 
 
He is considered a well-rounded and well-trained interventional cardiologist, given he has authored 82 publications, including 59 first-author peer-reviewed articles in top-tier journals such as European Heart Journal, JACC, JACC: Cardiovascular Interventions, Circulation: Cardiovascular Interventions, JSCAI, JAHA, Catheter Cardiovasc Interv, Am J Cardiol, and more. His work has been cited 800 times, reflecting an H-index of 16. The research has been cited and highly acclaimed by internationally renowned journals, including Nature Reviews Cardiology, The Lancet Global Health, European Heart Journal, JACC, and Circulation. His study has been incorporated into the American cardiology textbook <Interventional Cardiology: Principles and Practice, 3rd Edition>. Two studies (PMID: 37188864 and 34353593) were cited by the 2024 ESC Guidelines for the management of chronic coronary syndromes, with one (PMID: 37188864) achieving Class IIa Recommendation (Level A Evidence) and recognition as the top 10 cardiovascular studies in China in 2023. He previously won the TCTAP 2022 Best Young Scientist Award and the AHA 2021 Paul Dudley White International Scholar Award. Now he is the co-PI of the TARGET OLD trial (NCT05765370) and PI on the LM RICH trial.